Cargando…

Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report

Triple-negative breast cancer (TNBC) is highly aggressive disease that is often refractory to surgery and multiple lines of therapy. Although the repertoire of FDA-approved treatments has expanded, there is an unmet need for biomarkers that can aid in appropriate selection and timing of therapy. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azzi, Georges, Krinshpun, Shifra, Tin, Antony, Maninder, Minu, Malashevich, Allyson Koyen, Malhotra, Meenakshi, Vega, Ruben Ruiz, Billings, Paul R., Rodriguez, Angel, Aleshin, Alexey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149406/ https://www.ncbi.nlm.nih.gov/pubmed/35702676 http://dx.doi.org/10.1159/000524324

Ejemplares similares

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2021)

ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden
por: Schneider, Charles J., et al.
Publicado: (2021)

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant
por: Cohen, Stacey A., et al.
Publicado: (2022)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
por: Loupakis, Fotios, et al.
Publicado: (2021)

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
por: Huffman, Brandon M., et al.
Publicado: (2022)

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse
por: Dhakal, Binod, et al.
Publicado: (2022)

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Clinician‐reported chorionicity and zygosity assignment using single‐nucleotide polymorphism‐based cell‐free DNA: Lessons learned from 55,344 twin pregnancies
por: Wojas, Anna, et al.
Publicado: (2022)

Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma
por: Zhou, Maggie, et al.
Publicado: (2022)

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
por: Kasi, Pashtoon M., et al.
Publicado: (2022)

Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer
por: Weinberg, Benjamin A., et al.
Publicado: (2021)

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection
por: Ococks, Emma, et al.
Publicado: (2021)

Association Between Total Cell Free DNA and SARS-CoV-2 In Kidney Transplant Patients: A Preliminary Study
por: Reusing, Jose Otto, et al.
Publicado: (2022)

Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient
por: Yeakel, John, et al.
Publicado: (2021)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
por: Kansara, Maya, et al.
Publicado: (2022)

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients
por: Agelaki, Sofia, et al.
Publicado: (2016)

Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells
por: Abreu, Manuel, et al.
Publicado: (2020)

Post-operative ctDNA monitoring in stage I colon cancer: A case report
por: Alden, Stephanie L., et al.
Publicado: (2022)

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
por: Shang, Mao, et al.
Publicado: (2018)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

TEM8 specific T cells target the tumor cells and tumor-associated vasculature in triple negative breast cancer
por: Byrd, Tiara, et al.
Publicado: (2014)

The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis
por: Lu, Yan-jun, et al.
Publicado: (2016)

Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis
por: Gao, Chong, et al.
Publicado: (2019)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

Tumor Hypoxia and Circulating Tumor Cells
por: Tinganelli, Walter, et al.
Publicado: (2020)

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
por: Lindskrog, Sia V., et al.
Publicado: (2023)

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
por: Silvestri, Marco, et al.
Publicado: (2022)

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer()
por: Zheng, Xiumei, et al.
Publicado: (2017)

Emerging role of circulating tumor cells in immunotherapy
por: Rzhevskiy, Alexey, et al.
Publicado: (2021)

CIRCULATING TUMOR CELLS
por: Paiva, Bruno
Publicado: (2022)

Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China
por: Zhang, Yanwu, et al.
Publicado: (2017)

The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature
por: Lisencu, Lorena Alexandra, et al.
Publicado: (2022)

Molecular classification of triple-negative tumors
por: Prat, A, et al.
Publicado: (2011)

Successful treatment of triple primary tumor()()
por: Kurul, Sidika, et al.
Publicado: (2013)

Application of circulating tumor cells scope technique on circulating tumor cell research
por: Yang, Dawei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gi12pmqm1selupp20u14uut8ic